TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Objectives:
- To determine the response rate and duration of response with combination of TALL-104
cells and imatinib mesylate (IM) therapy in patients with chronic myelogenous leukemia
in chronic phase, that have not achieved, or have lost, adequate response to IM.
- To determine the toxicity of the combination of TALL-104 cells and IM therapy in this
patient population.